Euro Area and US composite PMIs currently point to a resilient but uneven recovery, with services carrying much of the load while manufacturing feels the strain of higher yields and energy costs. That creates a window in which cash rich companies with discounted valuations can draw fresh attention. This article looks at three stocks from the Undervalued Stocks Based On Cash Flows screener that may merit a closer look.

The stocks highlighted below are only a small sample of the opportunities that surfaced. The full screen identified 143 more companies with cash flows and valuations that may appeal to value focused investors but are not covered in this article. To go deeper into the full list, analyze their discounted cash flow assumptions, and identify the ideas that best match your playbook, head straight into the Undervalued Stocks Based On Cash Flows screener.

Broadcom (AVGO)

Overview: Broadcom is a large digital infrastructure company that designs semiconductor solutions for networking, wireless, storage and broadband. It also runs a sizeable infrastructure software portfolio through VMware, mainframe and software-as-a-service products that generate recurring, high-margin cash flows that are central to its cash-flow-based valuation appeal.

Operations: Broadcom generates about US$27.7b from Infrastructure Software and around US$47.8b from Semiconductor Solutions and intellectual property licensing, so its software cash flows are highly relevant to valuation even though semiconductors remain the larger revenue contributor.

Market Cap: US$1.75t

Broadcom provides exposure to AI-focused semiconductors and to VMware-driven infrastructure software that generates recurring, high-margin cash flows. These cash flows are important in an analysis built around discounted cash flow value. Strong profitability, high return on equity and a meaningful gap between the current share price and the Simply Wall St fair value estimate indicate that the market may be underpricing those cash flows. At the same time, high debt levels, complex AI financing structures and reliance on a small group of hyperscale customers mean the story involves notable risks. For investors seeking a closer look at a large-scale cash generator where software and hardware cash flows intersect, Broadcom may merit further attention.

Broadcom’s cash rich software and AI hardware engine may be masking a very different story once you factor in valuation, debt and customer concentration. Get the full picture in the 4 key rewards and 2 important warning signs

Build your own cash flow shortlist

Broadcom and the two other stocks in this piece all surfaced from a single Simply Wall St screener, which shows what is possible when cash flows and valuation filters work together. Create your own custom screen with our Screener to combine metrics such as valuation, balance sheet strength and dividends, or jump straight into our curated Investing Ideas for ready made shortlists.

MercadoLibre (MELI)

Overview: MercadoLibre runs the leading online marketplace and fintech ecosystem across Brazil, Mexico, Argentina and other Latin American markets, combining e commerce with Mercado Pago, a payments and digital finance platform. While the marketplace brings in a large share of revenue, the strongest link to the cash flow screener theme is Mercado Pago, which earns recurring cash flows from payments, digital wallets, short term investments through Mercado Fondo, lending via Mercado Credito and payment processing fees.

Operations: MercadoLibre generates about US$35.2b in revenue from internet software and services, primarily across Brazil, Mexico, Argentina and other Latin American countries.

Market Cap: US$97.5b

MercadoLibre may interest investors who care about cash flows, because Mercado Pago’s payments, lending and wallet business produces recurring financial-service cash flows that are central to a discounted cash flow (DCF) based valuation, while the marketplace and logistics network keep users highly engaged. The screener flags the stock as trading below its estimated fair value, even though the P/E multiple is high, because the DCF places more weight on those recurring fintech cash flows than on short term earnings. At the same time, high debt levels and reliance on external funding rather than customer deposits mean Mercado Pago’s funding costs and credit quality are important considerations. For readers who want to understand how that cash flow profile compares with the funding and credit risks, there is more to unpack beyond headline growth metrics.

MercadoLibre’s fast growing fintech flywheel and high P/E are only half the story. The real question is how those recurring cash flows stack up against funding and credit risks in the analysis report for MercadoLibre

Merck (MRK)

Overview: Merck is a global healthcare company best known for its human pharmaceuticals, led by the high cash flow oncology drug Keytruda alongside vaccines and other therapies, with additional contributions from animal health products. Its valuation link to this cash flow screener comes from Keytruda and a growing immuno oncology pipeline, which underpin expectations for long term cash generation rather than relying solely on smaller, diversified brands.

Operations: Merck generates about US$59.6b from human pharmaceuticals, US$6.7b from Animal Health and US$0.3b from other revenues, with the United States contributing US$37.7b of total sales and Europe, the Middle East and Africa adding US$15.3b.

Market Cap: US$376.4b

Merck offers a mix of high quality oncology cash flows and a discounted DCF valuation that value focused investors often look for in this screener. The company’s oncology franchise around Keytruda and newer programs like the Moderna partnered melanoma vaccine and ADC or bispecific deals is central to expectations for strong earnings growth and higher future cash flows, even as Keytruda’s exclusivity loss approaches. At the same time, thin current margins, a large one off loss, high debt and a dividend that is not well covered by earnings introduce real risk if pipeline execution slips. For investors who want a closer look at whether Merck’s growing pipeline can offset these pressures, there is more to unpack beneath the headline oncology story.

Merck’s oncology engine and growing pipeline could be reshaping the whole cash flow story. However, the real inflection point may sit in a few key programs. Get the full context in the full narrative for Merck

Seeking Alternatives Before The Crowd Moves

Fresh ideas can move quickly once momentum builds and prices start breaking out. Spot stocks still flying under the radar for now, before information decay kicks in and act now.

• Capture early momentum in resilient cash generators by scanning a curated list of solid balance sheet and fundamentals (50 results) while these businesses are still priced as if nothing has changed.
• Position ahead of potential yield seekers rotating into income stocks by checking the hand picked 12 dividend fortresses before payout momentum gets fully caught in the spotlight.
• Ride the next leg of AI infrastructure demand by reviewing the focused 55 AI infrastructure stocks while these picks remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.